NEW YORK, Dec. 03, 2018 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO), a developer and manufacturer of
biotherapeutics, today announced that it will present at the Plant-Based Technology Trends Meeting being held in Meireles,
Fortaleza, Brazil from December 2-4, 2018. The meeting is sponsored by Bio-Manguinhos/Fiocruz, a unit of the Brazilian Ministry of
Health.
Sancha Salgueiro, Ph.D., MBA, a well-known expert and business development executive focussed on plant-made
protein technologies and products, will be presenting:
-
Transient expression of therapeutic proteins in plants: a flexible platform for fast and affordable biologics
manufacturing
- Date and Time: December 4, 2018; 10:00 AM BRT
- Location: Fiocruz-CE Auditorium, Rua São José, s/n. Precabura, Eusébio-CE, Brazil
“I am honored to have this opportunity to highlight the significant product flexibility, time- and cost-savings
provided by iBio’s plant-based technology platform and CDMO offering to my fellow researchers and industry participants and, in so
doing, help support the development of new business relationships and commercial collaborations for iBio in Brazil and
internationally,” said Dr. Salgueiro.
“We are pleased to be invited to present at this international conference focusing on the latest advances and
achievements in the field of plant-based biopharmaceutical development and manufacture of recombinant antibodies and vaccines,”
said Robert B. Kay, iBio’s Chairman and CEO. “We look forward to continuing our collaborative relationship with
Bio-Manguinhos/Fiocruz as it implements its planned, important expansion of capabilities in the plant-based biopharmaceutical
field.”
About iBio, Inc.
iBio, a leader in developing plant-based biopharmaceuticals, provides a range of product and process
development, analytical, and manufacturing services at the large-scale development and manufacturing facility of its subsidiary
iBio CDMO, LLC in Bryan, Texas. The facility houses laboratory and pilot-scale operations, as well as large-scale automated
hydroponic systems capable of growing over four million plants as "in process inventory" and delivering over 300 kilograms of
therapeutic protein pharmaceutical active ingredient per year. For more information please visit www.ibioinc.com.
FORWARD-LOOKING STATEMENTS
STATEMENTS INCLUDED IN THIS NEWS RELEASE RELATED TO IBIO, INC. MAY CONSTITUTE FORWARD-LOOKING STATEMENTS WITHIN
THE MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. SUCH STATEMENTS INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES
SUCH AS COMPETITIVE FACTORS, TECHNOLOGICAL DEVELOPMENT, MARKET DEMAND, AND THE COMPANY'S ABILITY TO OBTAIN NEW CONTRACTS AND
ACCURATELY ESTIMATE NET REVENUES DUE TO VARIABILITY IN SIZE, SCOPE, AND DURATION OF PROJECTS. FURTHER INFORMATION ON POTENTIAL RISK
FACTORS THAT COULD AFFECT THE COMPANY'S FINANCIAL RESULTS CAN BE FOUND IN THE COMPANY'S REPORTS FILED WITH THE SECURITIES AND
EXCHANGE COMMISSION.
Contact:
Stephen Kilmer
Investor Relations
(646) 274-3580
skilmer@ibioinc.com
Source: iBio, Inc.